News Release

Large registry data demonstrates PCI for stable CAD can be safely performed before, during or after TAVR

STS/ACC TVT registry data analyzed long-term outcomes with S3 valve platform

Reports and Proceedings

Society for Cardiovascular Angiography and Interventions

SCAI Scientific Sessions 2024


SCAI Scientific Sessions 2024

view more 

Credit: Society for Cardiovascular Angiography & Interventions

Long Beach, Calif. – May 3, 2024 – New data reveals that percutaneous coronary intervention (PCI) can be safely performed before, during, or after transcatheter aortic valve replacement (TAVR) for patients with stable coronary artery disease (CAD). The results from the analysis were presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions.


For those with CAD, PCI and TAVR are often required to restore blood flow. Many clinicians prefer to conduct PCI before TAVR due to the potential complications that could occur during the replacement procedure. However, the optimal timing for PCI in patients undergoing TAVR is debatable.


The analysis included 49,344 patients with stable CAD who underwent PCI before (84.7%), after (1.3%), or simultaneously (14%) with TAVR using the Sapien 3 (S3) platform balloon expandable bioprosthesis. The analysis was conducted using the TVT Registry and Medicare linkage between 2015 and 2024.


In a propensity-matched analysis, the composite of all-cause mortality and stroke were similar in three groups at three years of follow-up. The authors noted that due to the small numbers of patients undergoing PCIs after the TAVR, when they compared just the two other groups (before and concomitant PCIs), PCI performed before TAVR had a slight advantage over concomitant PCI with TAVR at three years (P=0.012).


“These findings are exciting as they slightly differ from previously published registry data,” said Abhijeet Dhoble, MD, MPH, FACC, FSCAI, cardiologist at University of Texas Health Science Center at Houston, and lead author of the study. “We believe this data will instill confidence and provide supporting evidence for many physicians and heart teams to make decisions regarding the timing of PCI in patients undergoing TAVR.”


Session Details:

  • “Timing of Percutaneous Coronary Intervention in Conjunction with Transcatheter Aortic Valve Replacement with Balloon Expandable Valves in the United States”
  • Friday, May 3, 2024; 3:14-3:21 PM PT
  • Long Beach Convention Center, 104A, First Level




About Society for Cardiovascular Angiography & Interventions (SCAI)


The Society for Cardiovascular Angiography & Interventions, established in 1978, stands as the primary nonprofit medical society dedicated to representing invasive and interventional cardiology. SCAI's mission is to guide the global interventional cardiovascular community by fostering education, advocacy, research, and upholding standards for quality patient care. For more than 40 years, SCAI has exemplified professional excellence and innovation worldwide, cultivating a reputable community of over 4,500 members committed to advancing medical science and providing life-saving care for individuals, both adults and children, affected by cardiovascular disease. For more information, visit


For more information about the SCAI 2024 Scientific Sessions, visit Follow @SCAI on X (formerly Twitter) and on LinkedIn for the latest heart health news and use #SCAI2024 to follow the latest discussions.



Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.